India, July 15 -- Drug major Johnson & Johnson, while reporting slightly lower second-quarter profit despite sales growth, on Wednesday raised again its earnings and sales forecast for fiscal 2026. The company also announced a quarterly dividend.
In pre-market activity, the shares were losing around 1.9 percent, trading at $249.00, extending the 1.5% drop on Tuesday's regular trading close.
Joaquin Duato, Chairman and Chief Executive Officer, stated, "With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company's 140-year history."
For fiscal 2026, the company now projects adjusted earnings in a range of $11.60 to $11...